Table 1.
Characteristics of study population by donor type
| Characteristic | Haploidentical | Matched Unrelated | Cord Blood | P Value |
|---|---|---|---|---|
| No. of patients | 2894 | 11801 | 1487 | |
| No. of centers | 149 | 227 | 121 | |
| Age, median (range) | 55 (18-88) | 58 (18-83) | 50 (18-75) | <.01a |
| Sex (%) | <.01b | |||
| Male | 1722 (60) | 6832 (58) | 778 (52) | |
| Race (%) | <.01b | |||
| White | 2004 (69) | 10496 (89) | 1019 (69) | |
| Black or African American | 479 (17) | 253 (2) | 192 (13) | |
| Asian | 165 (6) | 307 (3) | 118 (8) | |
| Native Hawaiian/Pacific Islander | 15 (1) | 19 (0) | 13 (1) | |
| American Indian or Alaska Native | 10 (0) | 38 (0) | 11 (1) | |
| More than one race | 12 (0) | 27 (0) | 14 (1) | |
| Ethnicity (%) | <.01b | |||
| Hispanic or Latino | 356 (12) | 620 (5) | 214 (14) | |
| Non-Hispanic or non-Latino | 2211 (76) | 10133 (86) | 1126 (76) | |
| Non-resident of the U.S. | 269 (9) | 802 (7) | 112 (8) | |
| Karnofsky performance score <90 (%) | 1228 (42) | 5047 (43) | 511 (34) | <.01b |
| HCT-CI without obesity (%) | 0.01b | |||
| 0 | 678 (23) | 2504 (21) | 352 (24) | |
| 1 | 433 (15) | 1590 (13) | 226 (15) | |
| 2 | 416 (14) | 1838 (16) | 222 (15) | |
| 3 | 515 (18) | 2237 (19) | 277 (19) | |
| 4 | 369 (13) | 1517 (13) | 177 (12) | |
| 5+ | 478 (17) | 2102 (18) | 230 (15) | |
| Body Mass Index (BMI) (%) | <.01 | |||
| Median (range) | 28 (16-50) | 27 (16-50) | 26 (15-48) | |
| <18.5 | 45 (2) | 177 (1) | 31 (2) | |
| 18.5-24.9 | 875 (30) | 3732 (32) | 534 (36) | |
| 25-29.9 | 952 (33) | 4183 (35) | 506 (34) | |
| 30-34.9 | 629 (22) | 2273 (19) | 263 (18) | |
| 35+ | 393 (14) | 1436 (12) | 153 (10) | |
| Refined-Disease Risk Index (%) | <.01b | |||
| Low | 316 (11) | 1078 (9) | 134 (9) | |
| Intermediate | 1464 (51) | 6317 (54) | 851 (57) | |
| High | 752 (26) | 3029 (26) | 331 (22) | |
| Very high | 141 (5) | 416 (4) | 50 (3) | |
| Disease (%) | <.01b | |||
| AML | 1197 (41) | 5003 (42) | 732 (49) | |
| ALL | 433 (15) | 1508 (13) | 292 (20) | |
| CML | 119 (4) | 390 (3) | 39 (3) | |
| Other Leukemias | 108 (4) | 399 (3) | 39 (3) | |
| MDS | 447 (15) | 2358 (20) | 178 (12) | |
| MPN | 83 (3) | 590 (5) | 14 (1) | |
| NHL | 319 (11) | 1114 (9) | 148 (10) | |
| HD | 117 (4) | 189 (2) | 33 (2) | |
| MM | 62 (2) | 221 (2) | 9 (1) | |
| Non-MM PCD | 9 (0) | 29 (0) | 3 (0) | |
| Prior autologous transplant (%) | 303 (10) | 973 (8) | 102 (7) | <.01b |
| Graft source (%) | <.01b | |||
| Bone marrow | 974 (34) | 1606 (14) | 0 (0) | |
| Peripheral blood | 1920 (66) | 10195 (86) | 0 (0) | |
| Umbilical cord blood | 0 (0) | 0 (0) | 1487 (100) | |
| Number of cord blood units (%) | <.01b | |||
| 1 | 0 (0) | 0 (0) | 269 (18) | |
| 2 | 0 (0) | 0 (0) | 1218 (82) | |
| NA | 2894 (100) | 11801 (100) | 0 (0) | |
| TBI used in conditioning regimen (%) | 2100 (73) | 2680 (23) | 1245 (84) | <.01b |
| Conditioning Intensity (%) | <.01b | |||
| MAC | 1142 (39) | 6054 (51) | 724 (49) | |
| RIC | 823 (28) | 4102 (35) | 489 (33) | |
| NMA | 929 (32) | 1645 (14) | 274 (18) | |
| Donor/recipient sex match (%) | <.01b | |||
| M-M | 1092 (38) | 5169 (44) | 71 (5) | |
| M-F | 679 (23) | 3251 (28) | 71 (5) | |
| F-M | 630 (22) | 1644 (14) | 59 (4) | |
| F-F | 493 (17) | 1700 (14) | 55 (4) | |
| Double cord - recipient M | 0 (0) | 0 (0) | 642 (43) | |
| Double cord - recipient F | 0 (0) | 0 (0) | 576 (39) | |
| Double cord - Missing | 0 (0) | 0 (0) | 13 (1) | |
| Missing | 0 (0) | 37 (0) | 0 (0) | |
| Donor/recipient CMV serostatus (%) | <.01b | |||
| +/+ | 1300 (45) | 3289 (28) | 53 (4) | |
| +/− | 241 (8) | 1287 (11) | 32 (2) | |
| −/+ | 721 (25) | 3889 (33) | 64 (4) | |
| −/− | 615 (21) | 3277 (28) | 38 (3) | |
| Double cord - recipient + | 0 (0) | 0 (0) | 854 (57) | |
| Double cord - recipient − | 0 (0) | 0 (0) | 353 (24) | |
| Double cord - recipient CMV unknown | 0 (0) | 0 (0) | 12 (1) | |
| Missing | 17 (1) | 59 (0) | 81 (5) | |
| CD34+ dose, x 106/kg (BM only) (%) | <.01b | |||
| Median (25th-75th quartile) | 2.67 (1.75, 3.88) | 2.65 (1.75, 3.91) | ||
| 0-1.9 | 194 (7) | 453 (4) | ||
| 2-3.9 | 258 (9) | 612 (5) | ||
| 4-7.9 | 123 (4) | 304 (3) | ||
| ≥8 | 17 (1) | 37 (0) | ||
| NA (PBSC graft) | 1920 (66) | 10195 (86) | ||
| Missing | 382 (13) | 200 (2) | ||
| CD34+ dose, x 106/kg (PBSC) (%) | <.01b | |||
| Median (25th-75th quartile) | 5.12 (4.33, 7.68) | 6.39 (4.88, 8.64) | ||
| 0-1.9 | 77 (3) | 449 (4) | ||
| 2-3.9 | 156 (5) | 958 (8) | ||
| 4-7.9 | 645 (22) | 5057 (43) | ||
| ≥8 | 250 (9) | 2951 (25) | ||
| NA (BM graft) | 974 (34) | 1606 (14) | ||
| Missing | 792 (27) | 780 (7) | ||
| CD34+ dose, x 105/kg (CBU) (%) | ||||
| Single | ||||
| Median (IQR) | 2.31 (1.33, 4.34) | |||
| 0-1.9 | 84 (6) | |||
| 2-3.9 | 58 (4) | |||
| 4-7.9 | 30 (2) | |||
| ≥8 | 21 (1) | |||
| Missing | 76 (5) | |||
| Double | ||||
| Median (IQR) | 2.24 (1.45, 3.51) | |||
| 0-1.9 | 456 (31) | |||
| 2-3.9 | 378 (25) | |||
| 4-7.9 | 152 (10) | |||
| ≥8 | 63 (4) | |||
| Missing | 169 (11) | |||
| GVHD Prophylaxis (%) | <.01b | |||
| TAC + MMF ± others | 0 | 1381 (12) | 508 (34) | |
| TAC + MTX ± others (not MMF) | 0 | 6841 (58) | 26 (2) | |
| TAC ± others (not MMF, MTX) | 0 | 1214 (10) | 109 (7) | |
| CSA + MMF ± others (not TAC) | 0 | 650 (6) | 736 (50) | |
| CSA + MTX ± others (not MMF,TAC) | 0 | 853 (7) | 6 (<1) | |
| CSA ± others (not TAC, MMF, MTX) | 0 | 91 (<1) | 11 (<1) | |
| Other GVHD Prophylaxisc | 0 | 125 (1) | 79 (5) | |
| Posttransplant Cyclophosphamide ± others | 2844 (100) | 579 (5) | 7 (1) | |
| ATG/Alemtuzumab (%) | <.01b | |||
| ATG + Alemtuzumab | 54 (2) | 4086 (35) | 279 (19) | |
| ATG alone | 0 (0) | 1 (0) | 0 (0) | |
| Alemtuzumab alone | 2812 (97) | 7052 (60) | 1202 (81) | |
| Missing | 28 (1) | 662 (6) | 6 (0) | |
| Year of transplant (%) | <.01b | |||
| 2013 | 104 (4) | 1146 (10) | 231 (16) | |
| 2014 | 369 (13) | 2558 (22) | 375 (25) | |
| 2015 | 615 (21) | 2585 (22) | 343 (23) | |
| 2016 | 835 (29) | 2744 (23) | 302 (20) | |
| 2017 | 971 (34) | 2768 (23) | 236 (16) |
HCT-CI, hematopoietic cell transplantation-comorbidity index; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; HD, Hodgkin lymphoma; MM, multiple myeloma; N, number; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; NMA, nonmyeloablative conditioning; GVHD, graft-versus-host disease; CMV, cytomegalovirus; CBU, cord blood unit; MMF, mycophenolate mofetil; MTX, methotrexate; CSA, cyclosporine; TAC, tacrolimus; ATG, anti-thymocyte globulin; PBSC, peripheral blood stem cells; BM, bone marrow; NA, not applicable; IQR, interquartile range.
Hypothesis testing:
a
Kruskal-Wallis test
b
Pearson chi-square test
c
Other GVHD Prophylaxis: MMF or MTX + siro: n=84; Missing: n=120